Radiation therapy after radical surgery in prostate cancer

Radiation therapy plays a key role in the treatment of prostate cancer on its own. For higher risk diseases, the risk of recurrence following single modality therapy increases and a combination of treatment modalities may be necessary to achieve optimal results. We review clinical outcomes of adjuvant and salvage radiotherapy following radical prostatectomy, including disease-free survival, cancer-specific survival and overall survival. We also discuss when best to intervene with post-prostatectomy radiotherapy.

• Publication year

  2023

• Venue

  ecancermedicalscience

• Publication date

  2023-06-27

• Fields of study

  Medicine, Physics

• Identifiers
  DOI 10.3332/ecancer.2023.1565PMID 37396107PMCID 10310328
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer statistics, 2023

  2023cited by this paper
• Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death

  2023cited by this paper
• The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.

  2022influential reference
• Comparison of 68Ga-Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography Computed Tomography (PET-CT) and Whole-Body Magnetic Resonance Imaging (WB-MRI) with Diffusion Sequences (DWI) in the Staging of Advanced Prostate Cancer

  2021cited by this paper
• Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus -based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical Prostatectomy.

  2021cited by this paper
• Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death

  2021cited by this paper
• Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.

  2020cited by this paper
• Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations.

  2020cited by this paper
• Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.

  2020cited by this paper
• Hypofractionated post-prostatectomy radiotherapy for prostate cancer to reduce toxicity and improve patient convenience: A Phase I/II trial.

  2020cited by this paper
• Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.

  2020cited by this paper
• Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data.

  2020cited by this paper
• Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension.

  2019cited by this paper
• Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.

  2019influential reference
• Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

  2017influential reference
• Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy.

  2017cited by this paper
• Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial.

  2014cited by this paper
• Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911).

  2012cited by this paper
• Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial

  2010cited by this paper
• Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.

  2009cited by this paper
• Prostate cancer and health‐related quality of life: a review of the literature

  2002cited by this paper
• International Agency for Research on Cancer.

  1968cited by this paper

• ALDH1A3 Regulates Cellular Senescence and Senescence-Associated Secretome in Prostate Cancer

  2025cites this paper
• Differences in prostate cancer treatment receipt and timeliness of treatment between African American/Black and White Iowans

  2025cites this paper
• Early Alterations of Cytoskeletal Proteins Induced by Radiation Therapy in the Parenchymal Cells of Rat Major Salivary Glands: A Comparative Immunohistochemical Analysis

  2024cites this paper
• Multidisciplinary Approach in Prostate Cancer Management: Harmonizing the Role of Surgery, Radiation, and Systemic Therapy

  2024cites this paper
• Intracellular ascorbate is a safe-guard and/or reservoir for plasma vitamin C in prostate cancer patients undergoing radiotherapy.

  2023cites this paper
• Review of Current Treatment Intensification Strategies for Prostate Cancer Patients

  2023cites this paper